<DOC>
	<DOC>NCT00245466</DOC>
	<brief_summary>To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients</brief_summary>
	<brief_title>Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients</brief_title>
	<detailed_description>Degarelix was not FDA regulated at the time of the trial. After completion of the trial degarelix has been approved by the FDA and is thus an FDA regulated intervention (FDA regulated intervention is therefore ticked "YES"). The data include participants from both the main study (FE200486 CS02; NCT00819247) and the extension study FE200486 CS02A.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has completed study treatment in study FE200486 CS02. Has completed visit 16 in study FE200486 CS02. Has not met any withdrawal criteria up to and including visit 15 in FE200486 CS02</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>